Navigation Links
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
Date:4/15/2008

the six-month placebo-controlled trial showed that FTY720 reduced relapse rates by more than 50% compared to placebo. Current first-line therapies for MS reduced relapse rates by 30-35% on average in two-year studies.

Among patients originally on placebo who converted to active therapy in the extension, 51% were free of relapses at three years. The figure at two years was 57%.

FTY720 has been generally well tolerated throughout the three years of the Phase II study and its extension, with the most common adverse events being nasopharyngitis, headache, fatigue and influenza. Increases in alanine aminotransferase (liver enzymes) were observed in 16% of patients. Dermatological screening of patients was implemented in the extension after a small number of cases of localized skin malignancies were reported.

Novartis continues to study FTY720 in an ongoing, blinded Phase III clinical trial program. This program includes comprehensive monitoring that will further assess and characterize the safety profile of FTY720. For more information about the clinical trial program, including eligibility criteria and location of U.S. study sites, patients can call the following toll-free number: 866-788-3930, or visit http://www.MSClinicalTrials.com.

MS is caused by the destruction of myelin, which helps neurons carry electrical signals in the brain. The disease causes problems with muscle control and strength, vision, balance, sensation and mental function. MS typically presents in relapsing forms involving acute self-limiting attacks of neurological dysfunction (or "relapses") followed by complete or partial restoration of functions.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "planned", "potential", "would", "encouraging", "expected", "commitment", "may", "continues", "will", or similar expressions, or by expre
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
2. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
6. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
9. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
10. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
11. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... PARSIPPANY, N.J. , Aug. 3, 2015  LEO ... and Drug Administration (FDA) to include psoriasis as one ... Focused Drug Development Initiative i .  Psoriasis is an ... lives and subsequent comorbidities, affecting 7.5 million people in ... of LEO Pharma,s ongoing commitment to supporting patients living ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Researchers at Brigham and Women,s,Hospital found that patients taking ... effects were unrelated to relief from their pain,symptoms. ... examine the addictive,potential of this class of pain medicine, ... 25th Annual Meeting. , In ...
... Lethal ,Super, Strains of C.difficileCHICAGO, Jan. 28 ... scientists at The University of Nottingham are leading a ... one of the most lethal strains of hospital acquired ... technology developed in Nottingham to study the function of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... other long-term care facilities, today announced details of the Advanced level of their ... centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is based ...
(Date:8/4/2015)... Vegas, Nevada (PRWEB) , ... August 04, 2015 ... ... FEMALE, a striking contemporary look at unique artistic expressions from a diverse group ... inside the Life Is Beautiful Music & Art Festival on September 25-27, 2015 ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may ... to driving, says the August 2015 Harvard Health Letter. , "Age and health ... requires an individual assessment of skills," says Lissa Kapust, a social worker at ...
(Date:8/4/2015)... ... August 04, 2015 , ... METTLER TOLEDO has announced ... featuring researchers from Lubrizol, Pfizer, and Merck. This free online seminar will ... project timelines often require informed decisions with limited process understanding. Established methods ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2
... ... conducted by the US Department of Health and Human Services. , ... Austin, TX (PRWEB) September 25, 2009 -- RCRC Independent ... will provide oversight of research supported or conducted by a federal department or agency within ...
... and weight are shaped by their social class, according to ... Policymakers have long insisted on the importance of ... the first study to show how everyday practices and perceptions ... weight and health of teenagers. ,It is evident that ...
... says it will review procedure for endorsing medical devices ... Food and Drug Administration violated procedures last year when ... own scientists recommended against approval, agency officials said Thursday. ... Jersey-based ReGen Biologics and is used to help surgically ...
... SAN FRANCISCO, CA SEPTEMER 24, 2009 Results ... that the combination of giving patients clopidogrel, a blood ... stomach medicines such as omeprazole, known as proton pump ... some prior studies had suggested. The results were presented ...
... , , NEW YORK, Sept. ... Ashoka will partner to create the first international fellowship program ... improve maternal health in developing countries. The Maternal Health Task ... Maternal Health Program as a commitment to action at the ...
... , , , ... Health Registry is expanding its service area across Oklahoma by partnering ... Web service on November 1st, 2009. , , ... has nearly doubled from 1.3 million people served by the Emergency ...
Cached Medicine News:Health News:RCRC Independent Review Board Announces DHHS Research Oversight 2Health News:Social background weighs heavily on teenage diet 2Health News:FDA Acknowledges Mistakes in Knee-Device Approval 2Health News:Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 3Health News:Oklahoma Medics Embracing iB Web Service 2
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: